Fig. 2
Immune reconstitution related EBV infections and letermovir prophylaxis following allo-HCT. Analysis of the relative IFN-γ release ability by PBMCs in different groups at different timepoints following allo-HCT (A); Results of the PLS-DA, showing lymphocyte recovery in the first 3 months after allo-HCT in patients with no EBV infection, EBV DNAemia (without subsequent PTLD, thereafter)/EBV-disease and PTLD, respectively (B); In comparison to patients without EBV infection, CD8+ T cell recovery was progressively impaired in patients with DNAemia/EBV-disease and PTLD (no EBV infection > DNAemia/EBV-disease > PTLD) in the first month after allo-HCT (C); Comparison of naïve CD8+ T (TN, CD8+CD45RA+CD27+) (D), central memory CD8+ T (TCM, CD8+CD45RA−CD27+) (E), effector memory CD8+ T (TEM, CD8+CD45RA−CD27−) (F), and terminally differentiated TEM (TEMRA, CD8+CD45RA+CD27−) CD8+ T cells (G) among patients with no EBV infection (n = 33), EBV DNAemia/EBV-disease (n = 25), or EBV-disease/PTLD (n = 6); Results of the PLS-DA, showing lymphocyte recovery in the first 3 months following allo-HCT in the letermovir and control groups, respectively (H); Results of the PLS-DA, showing lymphocyte recovery in patients without EBV infection (I), patients with EBV DNAemia/EBV-disease (J), or PTLD patients (K) in the first 3 months following allo-HCT in the letermovir and control groups, respectively; The effect of letermovir prophylaxis on the CD8+ T cell recovery trajectory (L). *P < 0.05, **P < 0.01, ***P < 0.001. Data about lymphocyte count are presented after logarithmic conversion. ‘Patients with EBV DNAemia’ refers to those patients without subsequent EBV-disease/PTLD occurrences